USRE46276E1 - Triazolo(4,5-D)pyrimidine compounds - Google Patents
Triazolo(4,5-D)pyrimidine compounds Download PDFInfo
- Publication number
- USRE46276E1 USRE46276E1 US14/976,977 US199914976977A USRE46276E US RE46276 E1 USRE46276 E1 US RE46276E1 US 199914976977 A US199914976977 A US 199914976977A US RE46276 E USRE46276 E US RE46276E
- Authority
- US
- United States
- Prior art keywords
- triazolo
- pyrimidin
- amino
- cyclopropyl
- difluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 0 *[C@H]1C[C@@H](N2N=NC3=C2N=C(S[1*])N=C3C[C@@H]2C[C@H]2[2*])[C@H]([3*])[C@@H]1[4*] Chemical compound *[C@H]1C[C@@H](N2N=NC3=C2N=C(S[1*])N=C3C[C@@H]2C[C@H]2[2*])[C@H]([3*])[C@@H]1[4*] 0.000 description 19
- AGCCOKROZDYAMR-GHNGIAPOSA-N CC1C(C)[C@@H]2C[C@H]1CC2=O Chemical compound CC1C(C)[C@@H]2C[C@H]1CC2=O AGCCOKROZDYAMR-GHNGIAPOSA-N 0.000 description 1
- IQGYCVKWCYGVBK-UHFFFAOYSA-N NC1=C(N)C(S)=NC(S)=N1 Chemical compound NC1=C(N)C(S)=NC(S)=N1 IQGYCVKWCYGVBK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/40—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/976,977 USRE46276E1 (en) | 1998-12-04 | 1999-12-02 | Triazolo(4,5-D)pyrimidine compounds |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9804211 | 1998-12-04 | ||
SE9804211A SE9804211D0 (sv) | 1998-12-04 | 1998-12-04 | Novel compounds |
SE9901271A SE9901271D0 (sv) | 1999-04-09 | 1999-04-09 | Novel compounds |
SE9901271 | 1999-04-09 | ||
US50819599A | 1999-12-02 | 1999-12-02 | |
PCT/SE1999/002256 WO2000034283A1 (en) | 1998-12-04 | 1999-12-02 | Novel triazolo(4,5-d)pyrimidine compounds |
US14/976,977 USRE46276E1 (en) | 1998-12-04 | 1999-12-02 | Triazolo(4,5-D)pyrimidine compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE46276E1 true USRE46276E1 (en) | 2017-01-17 |
Family
ID=26663448
Family Applications (12)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/508,195 Ceased US6525060B1 (en) | 1998-12-04 | 1999-12-02 | Triazolo(4,5-d)pyrimidine compounds |
US14/976,977 Active 2024-10-30 USRE46276E1 (en) | 1998-12-04 | 1999-12-02 | Triazolo(4,5-D)pyrimidine compounds |
US10/323,655 Expired - Lifetime US6974868B2 (en) | 1998-12-04 | 2002-12-20 | Compounds |
US11/230,493 Expired - Lifetime US7250419B2 (en) | 1998-12-04 | 2005-09-21 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US11/711,838 Abandoned US20070265282A1 (en) | 1998-12-04 | 2007-02-28 | Novel compounds |
US12/149,771 Abandoned US20080214812A1 (en) | 1998-12-04 | 2008-05-08 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US12/591,395 Abandoned US20100069408A1 (en) | 1998-12-04 | 2009-11-18 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US13/137,125 Abandoned US20120165348A1 (en) | 1998-12-04 | 2011-07-21 | Novel compounds |
US13/423,848 Abandoned US20130072503A1 (en) | 1998-12-04 | 2012-03-19 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US13/665,241 Abandoned US20130109702A1 (en) | 1998-12-04 | 2012-10-31 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US14/068,942 Abandoned US20140296258A1 (en) | 1998-12-04 | 2013-10-31 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibiton |
US14/310,315 Abandoned US20150152111A1 (en) | 1998-12-04 | 2014-06-20 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/508,195 Ceased US6525060B1 (en) | 1998-12-04 | 1999-12-02 | Triazolo(4,5-d)pyrimidine compounds |
Family Applications After (10)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/323,655 Expired - Lifetime US6974868B2 (en) | 1998-12-04 | 2002-12-20 | Compounds |
US11/230,493 Expired - Lifetime US7250419B2 (en) | 1998-12-04 | 2005-09-21 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US11/711,838 Abandoned US20070265282A1 (en) | 1998-12-04 | 2007-02-28 | Novel compounds |
US12/149,771 Abandoned US20080214812A1 (en) | 1998-12-04 | 2008-05-08 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US12/591,395 Abandoned US20100069408A1 (en) | 1998-12-04 | 2009-11-18 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US13/137,125 Abandoned US20120165348A1 (en) | 1998-12-04 | 2011-07-21 | Novel compounds |
US13/423,848 Abandoned US20130072503A1 (en) | 1998-12-04 | 2012-03-19 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US13/665,241 Abandoned US20130109702A1 (en) | 1998-12-04 | 2012-10-31 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US14/068,942 Abandoned US20140296258A1 (en) | 1998-12-04 | 2013-10-31 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibiton |
US14/310,315 Abandoned US20150152111A1 (en) | 1998-12-04 | 2014-06-20 | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
Country Status (36)
Country | Link |
---|---|
US (12) | US6525060B1 (ja) |
EP (5) | EP1386921B1 (ja) |
JP (4) | JP4202607B2 (ja) |
KR (4) | KR100822602B1 (ja) |
CN (1) | CN1128801C (ja) |
AR (3) | AR023920A1 (ja) |
AT (3) | ATE261970T1 (ja) |
AU (1) | AU766618B2 (ja) |
BR (1) | BRPI9915883B8 (ja) |
CA (1) | CA2351709C (ja) |
CY (3) | CY1110501T1 (ja) |
CZ (3) | CZ295234B6 (ja) |
DE (4) | DE69940171D1 (ja) |
DK (3) | DK1386921T3 (ja) |
EG (1) | EG24814A (ja) |
ES (3) | ES2318081T3 (ja) |
FR (1) | FR11C0016I2 (ja) |
HK (3) | HK1039933B (ja) |
HU (2) | HU228589B1 (ja) |
ID (1) | ID29927A (ja) |
IL (6) | IL143232A0 (ja) |
LT (1) | LTC1135391I2 (ja) |
LU (1) | LU91819I2 (ja) |
MY (1) | MY121867A (ja) |
NO (2) | NO319806B1 (ja) |
NZ (1) | NZ511778A (ja) |
PL (1) | PL201283B1 (ja) |
PT (2) | PT1386921E (ja) |
RU (3) | RU2317990C2 (ja) |
SA (1) | SA99200848B1 (ja) |
SI (3) | SI1386921T1 (ja) |
SK (1) | SK286007B6 (ja) |
TR (1) | TR200101567T2 (ja) |
TW (1) | TWI229674B (ja) |
WO (1) | WO2000034283A1 (ja) |
ZA (1) | ZA200104094B (ja) |
Families Citing this family (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
SE9903290D0 (sv) | 1999-09-15 | 1999-09-15 | Astra Pharma Prod | Novel compounds |
SE9904129D0 (sv) | 1999-11-15 | 1999-11-15 | Astra Pharma Prod | Novel compounds |
SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
GB0013488D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
TWI290549B (en) * | 2000-06-02 | 2007-12-01 | Astrazeneca Ab | Process for the preparation of cyclopropyl carboxylic acid ester and derivatives |
US6897201B2 (en) | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
US7132408B2 (en) | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
US7435724B2 (en) | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
EP1650192A4 (en) | 2003-07-24 | 2007-03-21 | Astellas Pharma Inc | QUINOLONE DERIVATIVE OR SALT THEREOF |
SE0401001D0 (sv) | 2004-03-31 | 2004-03-31 | Astrazeneca Ab | Chemical process |
SE0400873D0 (sv) * | 2004-03-31 | 2004-03-31 | Astrazeneca Ab | Chemical process |
WO2007020935A1 (ja) * | 2005-08-17 | 2007-02-22 | Ono Pharmaceutical Co., Ltd. | P2y12受容体および/またはp2y14受容体ブロッカーを含有してなる疼痛治療剤 |
TWI391378B (zh) | 2006-03-16 | 2013-04-01 | Astellas Pharma Inc | 喹啉酮衍生物或其製藥學上可被容許之鹽 |
GB0615620D0 (en) | 2006-08-05 | 2006-09-13 | Astrazeneca Ab | A process for the preparation of optically active intermediates |
TWI482772B (zh) * | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
WO2008024044A1 (en) * | 2006-08-21 | 2008-02-28 | Astrazeneca Ab | Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate |
US7566722B2 (en) * | 2006-10-31 | 2009-07-28 | Janssen Pharmaceutica, N.V. | Triazolopyrimidine derivatives as ADP P2Y12 receptor antagonists |
TWI496776B (zh) * | 2007-11-15 | 2015-08-21 | Astrazeneca Ab | 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法 |
UA100864C2 (uk) | 2007-12-03 | 2013-02-11 | Астразенека Аб | Спосіб лікування або запобігання аневризмі черевної аорти |
TWI389913B (zh) * | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
ES2558843T3 (es) | 2008-09-09 | 2016-02-09 | Astrazeneca Ab | Procedimiento para preparar [1S-[1-alfa,2-alfa,3-beta(1S*,2R*),5-beta]]-3-[7-[2-(3,4-difluorofenil)-ciclopropilamino]-5-(propiltio)-3H-1,2,3-triazolo[4,5-d]pirimidin-3-il]-5-(2-hidroxietoxi)ciclopentano-1,2-diol y a sus productos intermedios |
EP2361242B1 (en) | 2008-10-17 | 2018-08-01 | Oryzon Genomics, S.A. | Oxidase inhibitors and their use |
WO2010084160A1 (en) | 2009-01-21 | 2010-07-29 | Oryzon Genomics S.A. | Phenylcyclopropylamine derivatives and their medical use |
EP2459564B1 (en) | 2009-07-27 | 2016-09-07 | Auspex Pharmaceuticals, Inc. | Cyclopropyl modulators of p2y12 receptor |
EP2305376A1 (en) | 2009-09-23 | 2011-04-06 | Lonza Ltd. | Process and catalyst for the catalytic hydrogenation of aromatic and heteroaromatic nitro compounds |
MX338041B (es) | 2009-09-25 | 2016-03-30 | Oryzon Genomics Sa | Inhibidores de demetilasa-1 especificos de lisina y su uso. |
EP2486002B1 (en) | 2009-10-09 | 2019-03-27 | Oryzon Genomics, S.A. | Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use |
CA2781182A1 (en) | 2009-12-03 | 2011-06-09 | Astrazeneca Ab | Co - crystals of a triazolo [4,5 - d] pyrimidine platelet aggregation inhibitor |
EA026094B1 (ru) | 2009-12-23 | 2017-03-31 | Рациофарм Гмбх | Твердая лекарственная форма тикагрелора |
CA2788072A1 (en) | 2010-02-16 | 2011-08-25 | Actavis Group Ptc Ehf | Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine |
US9186337B2 (en) | 2010-02-24 | 2015-11-17 | Oryzon Genomics S.A. | Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae |
US9616058B2 (en) | 2010-02-24 | 2017-04-11 | Oryzon Genomics, S.A. | Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use |
KR101794020B1 (ko) | 2010-04-19 | 2017-11-06 | 오리존 지노믹스 에스.에이. | 라이신 특이적 디메틸라아제-1 억제제 및 이의 용도 |
EP2560939A2 (en) | 2010-04-20 | 2013-02-27 | Actavis Group Ptc Ehf | Novel process for preparing phenylcyclopropylamine derivatives using novel intermediates |
RU2013103794A (ru) | 2010-06-30 | 2014-08-10 | Актавис Груп Птс Ехф | Новые способы получения производных фенилциклопропиламина и их применение для получения тикагрелора |
US9181198B2 (en) | 2010-07-29 | 2015-11-10 | Oryzon Genomics S.A. | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use |
WO2012013727A1 (en) | 2010-07-29 | 2012-02-02 | Oryzon Genomics S.A. | Cyclopropylamine derivatives useful as lsd1 inhibitors |
WO2012045883A1 (en) | 2010-10-08 | 2012-04-12 | Oryzon Genomics S.A. | Cyclopropylamine inhibitors of oxidases |
WO2012063126A2 (en) | 2010-11-09 | 2012-05-18 | Actavis Group Ptc Ehf | Improved processes for preparing pure (3ar,4s,6r,6as)-6-amino-2,2-dimethyltetrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol and its key starting material |
WO2012072713A2 (en) | 2010-11-30 | 2012-06-07 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae |
MX2013007115A (es) | 2010-12-20 | 2014-02-10 | Actavis Group Ptc Ehf | Procesos novedosos para preparar derivados de triazolo[4, 5 - d] pirimidina e intermediarios de los mismos. |
EP2712315B1 (en) | 2011-02-08 | 2021-11-24 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for myeloproliferative disorders |
CN102653539B (zh) * | 2011-03-01 | 2014-09-17 | 秦引林 | 一种抗血小板聚集化合物及其药物组合 |
CA2832570A1 (en) | 2011-04-06 | 2012-10-11 | Teva Pharmaceutical Industries Ltd. | New intermediates and processes for preparing ticagrelor |
CN102731510B (zh) * | 2011-04-07 | 2015-12-16 | 博瑞生物医药(苏州)股份有限公司 | 替卡格雷的衍生物、制备方法及其药物用途 |
CZ2011229A3 (cs) * | 2011-04-19 | 2012-08-15 | Zentiva, K.S. | Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy |
BR112013028936B1 (pt) * | 2011-05-13 | 2021-10-19 | Astrazeneca Ab | Processo para a preparação de benzil [(3as,4r,6s,6ar)-6-hidróxi-2,2-dimetiltetra-hidro- 3ahciclopenta[d]dioxol]-4-il]carbamato e compostos intermediários no processo |
WO2012156537A2 (en) * | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for thrombosis and cardiovascular diseases |
WO2012156531A2 (en) * | 2011-05-19 | 2012-11-22 | Oryzon Genomics, S.A. | Lysine demethylase inhibitors for inflammatory diseases or conditions |
KR20140028011A (ko) | 2011-06-01 | 2014-03-07 | 아스트라제네카 아베 | 신규한 티카그렐러 공결정 |
US20140206867A1 (en) | 2011-06-15 | 2014-07-24 | Actavis Group Ptc Ehf | Process for Preparing Cyclopentylamine Derivatives and Intermediates Thereof |
CN102924457A (zh) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | 三唑并嘧啶类衍生物、其制备方法及其用途 |
EP2570405A1 (en) | 2011-09-14 | 2013-03-20 | LEK Pharmaceuticals d.d. | Synthesis of Triazolopyrimidine Compounds |
HUE031673T2 (en) | 2011-09-14 | 2017-07-28 | Lek Pharmaceuticals | Synthesis of triazolopyrimidine compounds |
CN107266345B (zh) | 2011-10-20 | 2021-08-17 | 奥瑞泽恩基因组学股份有限公司 | 作为lsd1抑制剂的(杂)芳基环丙胺化合物 |
RS58475B1 (sr) | 2011-10-20 | 2019-04-30 | Oryzon Genomics Sa | Jedinjenja (hetero)aril ciklopropilamina kao lsd1 inhibitori |
WO2013060837A1 (en) | 2011-10-27 | 2013-05-02 | Lek Pharmaceuticals D.D. | Synthesis of triazolopyrimidine compounds |
EP2586773A1 (en) | 2011-10-27 | 2013-05-01 | LEK Pharmaceuticals d.d. | Synthesis of Triazolopyrimidine Compounds |
EP2589587A1 (en) | 2011-11-04 | 2013-05-08 | Chemo Ibérica, S.A. | Synthesis of nitrogen substituted cyclopropanes |
BR112014013085A2 (pt) | 2011-11-30 | 2017-06-13 | Actavis Group Ptc Ehf | forma cristalina do ticagrelor, processo para a preparação da forma cristalina do ticagrelor, composição farmacêutica e processo para preparar uma composição farmacêutica |
EP2607355A1 (en) * | 2011-12-23 | 2013-06-26 | LEK Pharmaceuticals d.d. | Synthesis of triazolopyrimidine compounds |
EP2794575B1 (en) * | 2011-12-23 | 2018-12-05 | LEK Pharmaceuticals d.d. | Synthesis of triazolopyrimidine compounds |
EP2628721A1 (en) | 2012-02-20 | 2013-08-21 | LEK Pharmaceuticals d.d. | Synthesis of 2-(3,4-difluorophenyl)cyclopropanecarboxylic acid |
EP2644590A1 (en) | 2012-03-30 | 2013-10-02 | LEK Pharmaceuticals d.d. | Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts |
CN104603098B (zh) | 2012-03-30 | 2016-06-29 | 桑多斯股份公司 | 2-(3,4-二氟苯基)环丙胺衍生物和盐的合成 |
WO2013150495A2 (en) | 2012-04-05 | 2013-10-10 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
WO2013163892A1 (en) * | 2012-05-02 | 2013-11-07 | Sunshine Lake Pharma Co., Ltd. | Novel triazolo pyrimidine compounds and a process of preparation thereof |
CN102659815B (zh) * | 2012-05-04 | 2013-07-17 | 开原亨泰制药股份有限公司 | 一种制备选择性抗凝血药替卡格雷及其中间体的方法 |
EP2666771A1 (en) | 2012-05-24 | 2013-11-27 | LEK Pharmaceuticals d.d. | Synthesis of Aminocyclopentanetriol Derivatives |
ITMI20121142A1 (it) * | 2012-06-28 | 2013-12-29 | Chemo Iberica Sa | Processo chemoenzimatico per la produzione di fenil ciclopropilammine |
BR112014032085A2 (pt) * | 2012-06-29 | 2017-06-27 | Zentiva Ks | solvato de ticagrelor, processos para a preparação de um solvato e para a preparação de um cocristal, cocristal de ticagrelor, e, usos de um solvato e de um cocristal |
WO2014006091A1 (en) | 2012-07-04 | 2014-01-09 | Lek Pharmaceuticals D.D. | Ticagrelor adducts with divalent metal salts |
CN103626743B (zh) * | 2012-08-23 | 2018-06-08 | 广东东阳光药业有限公司 | 替卡格雷的新型中间体及其制备方法 |
CN102875537A (zh) * | 2012-09-10 | 2013-01-16 | 常州制药厂有限公司 | 一种新的抗血栓药物的制备方法 |
CZ2012705A3 (cs) | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
WO2014083139A1 (en) | 2012-11-29 | 2014-06-05 | Actavis Group Ptc Ehf | Novel amorphous form of ticagrelor |
WO2014102830A1 (en) | 2012-12-31 | 2014-07-03 | Megafine Pharma (P) Ltd. | A process for preparation of ticagrelor and intermediates thereof |
CN104045620B (zh) * | 2013-03-12 | 2017-05-10 | 博瑞生物医药(苏州)股份有限公司 | 一种替卡格雷中间体的制备方法 |
CZ307217B6 (cs) | 2013-03-14 | 2018-04-04 | Zentiva, K.S. | Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru |
IN2013MU01111A (ja) * | 2013-03-25 | 2015-05-01 | Glenmark Generics Ltd | |
ITMI20130487A1 (it) | 2013-03-29 | 2014-09-30 | Chemo Res S L | Alchilazione selettiva di ciclopentilalcoli |
CN107573333B (zh) | 2013-04-10 | 2019-10-18 | 江苏恒瑞医药股份有限公司 | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 |
EP2813216A1 (en) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Stabilized amorphous ticagrelor |
WO2014170026A1 (en) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
CN104230818B (zh) * | 2013-06-06 | 2018-01-12 | 郝聪梅 | 替卡格雷中间体的改进制备方法 |
EP2816043A1 (en) | 2013-06-21 | 2014-12-24 | LEK Pharmaceuticals d.d. | Spherical ticagrelor particles |
WO2014206187A1 (zh) | 2013-06-24 | 2014-12-31 | 苏州明锐医药科技有限公司 | 替卡格雷及其中间体的制备方法 |
CN104250251B (zh) * | 2013-06-25 | 2017-05-17 | 上海京新生物医药有限公司 | 一种替格瑞洛的制备方法 |
WO2015001489A1 (en) | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of ticagrelor |
CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
CN103992323B (zh) * | 2014-04-18 | 2017-03-29 | 南通常佑药业科技有限公司 | 一种替格瑞洛的制备方法 |
WO2015162630A1 (en) | 2014-04-25 | 2015-10-29 | Anlon Chemical Research Organization | Novel processes for preparing triazolo [4,5-d]- pyrimidines, including ticagrelor, vianew intermediates and new route of synthesis. |
DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
US10011605B2 (en) | 2014-06-18 | 2018-07-03 | Flamma Spa | Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds |
CN105272985B (zh) * | 2014-06-24 | 2017-11-21 | 珠海联邦制药股份有限公司 | 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物 |
WO2016001851A1 (en) * | 2014-07-02 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
US9982061B2 (en) * | 2014-10-01 | 2018-05-29 | Medimmune Limited | Antibodies to ticagrelor and methods of use |
WO2016116942A1 (en) | 2015-01-20 | 2016-07-28 | Anlon Chemical Research Organization | Novel pharmaceutical compounds comprising ticagrelor with salts of aspirin |
CN105985346B (zh) * | 2015-03-06 | 2019-10-18 | 苏州朗科生物技术股份有限公司 | 一种新的替格瑞洛化合物制备方法及其中间体化合物 |
US9789087B2 (en) | 2015-08-03 | 2017-10-17 | Thomas Jefferson University | PAR4 inhibitor therapy for patients with PAR4 polymorphism |
CN105237540B (zh) * | 2015-09-21 | 2017-10-03 | 南京正大天晴制药有限公司 | 一种替格瑞洛有关物质的制备方法、检测方法及用途 |
US20190002471A1 (en) | 2016-01-05 | 2019-01-03 | Amneal Pharmaceuticals Company Gmbh | Crystalline Form Of Ticagrelor |
TR201601835A2 (tr) | 2016-02-12 | 2017-08-21 | Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi | Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇ |
US20170296666A1 (en) | 2016-04-18 | 2017-10-19 | Amneal Pharmaceuticals Company Gmbh | Stable Pharmaceutical Composition Of Amorphous Ticagrelor |
EA201892150A1 (ru) | 2016-04-21 | 2019-05-31 | Астразенека Аб | Распадающиеся в полости рта таблетки |
RU2019108464A (ru) * | 2016-08-26 | 2020-09-28 | Мицубиси Танабе Фарма Корпорейшн | Бициклическое азотсодержащее гетероциклическое соединение |
DK3292867T3 (da) | 2016-09-09 | 2019-07-22 | Univ Liege | Ny brug af triazol(4,5-d)pyrimidinderivater til brug i forebyggelsen og behandlingen af bakteriel infektion |
US10905691B2 (en) | 2016-09-09 | 2021-02-02 | Université de Liège | Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection |
CN107814772A (zh) * | 2017-11-24 | 2018-03-20 | 常州沃腾化工科技有限公司 | 4,6‑二氯‑5‑氨基‑2‑丙硫基嘧啶酯的精制方法 |
EP3527571A1 (en) * | 2018-02-14 | 2019-08-21 | Université de Liège | Pyrimidine derivatives for prevention and treatment of bacterial infection |
WO2020021110A1 (en) | 2018-07-27 | 2020-01-30 | Krka, D.D., Novo Mesto | Pharmaceutical composition of ticagrelor |
CN109761785A (zh) * | 2019-02-16 | 2019-05-17 | 安徽诺全药业有限公司 | 一种(1r,2r)-2-(3,4-二氟苯基)环丙烷羧酸的合成方法 |
GB201910656D0 (en) | 2019-07-25 | 2019-09-11 | Univ Liege | New use of triazolo(4,5-d)Pyrimidine deerivatives |
EP3919497A1 (en) | 2020-06-04 | 2021-12-08 | Zaklady Farmaceutyczne Polpharma S.A. | Process for the preparation of ticagrelor |
CN112876485A (zh) * | 2021-01-25 | 2021-06-01 | 郭丽伟 | 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物 |
EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
WO2023213198A1 (zh) * | 2022-05-04 | 2023-11-09 | 华东师范大学 | 芳香稠环化合物作为trek-1激活剂的用途、包含其的药物组合物、镇痛剂 |
Citations (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3106578A (en) | 1960-09-16 | 1963-10-08 | Smith Kline French Lab | Nu-phenethyl-2-phenylcyclopropylamine derivatives |
US3509129A (en) | 1967-06-08 | 1970-04-28 | Boehringer & Soehne Gmbh | Adenosine derivatives |
US3590029A (en) | 1967-08-25 | 1971-06-29 | Boehringer Mannheim Gmbh | 2-amino-adenosine derivatives |
CA994773A (en) | 1971-05-17 | 1976-08-10 | Hanspeter Fischer | 5-nitro-2,4-bis-amino-2-alkylthiopyrimidines |
US4016204A (en) | 1975-10-31 | 1977-04-05 | Nelson Research & Development Company | Method of synthesis of trans-2-phenylcyclopropylamine |
US4543255A (en) | 1984-05-10 | 1985-09-24 | Southern Research Institute | Carbocyclic analogs of purine 2'-deoxyribofuranosides |
US4742064A (en) | 1985-09-10 | 1988-05-03 | Regents Of The University Of Minnesota | Antiviral carbocyclic analogs of xylofuranosylpurines |
GB2217320A (en) | 1988-01-20 | 1989-10-25 | Univ Minnesota | Dideoxydidehydrocarbocyclic nucleosides |
WO1990006671A2 (en) | 1988-12-12 | 1990-06-28 | Palese Peter M | Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections |
WO1991007405A1 (en) | 1989-11-13 | 1991-05-30 | The Board Of Regents Of Oklahoma State University | Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof |
WO1992012718A1 (en) | 1991-01-23 | 1992-08-06 | Gensia, Inc. | Adenosine kinase inhibitors |
WO1992017488A1 (en) | 1991-04-06 | 1992-10-15 | Fisons Plc | Atp analogues |
EP0521463A2 (de) | 1991-07-04 | 1993-01-07 | Hoechst Aktiengesellschaft | Cyclisch substituierte Cycloalkyltriole, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie ihre Verwendung als antivirale und antiparasitäre Mittel |
US5288726A (en) | 1991-09-09 | 1994-02-22 | Ube Industries Limited | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
US5338725A (en) | 1992-06-30 | 1994-08-16 | The Research Foundation Of The State University Of New York | Anti-aggregatory agents for platelets |
WO1994017803A1 (en) | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors |
WO1994018216A1 (en) | 1993-02-10 | 1994-08-18 | Astra Pharmaceuticals Limited | N-alkyl-2-substituted atp analogues |
WO1996029345A1 (en) | 1995-03-23 | 1996-09-26 | The Trustees Of The University Of Pennsylvania | Novel inotropic agents |
WO1996040686A1 (en) | 1995-06-07 | 1996-12-19 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
WO1997003084A1 (en) | 1995-07-11 | 1997-01-30 | Astra Pharmaceuticals Ltd. | New inhibitors of platelet aggregation |
US5620676A (en) | 1994-03-08 | 1997-04-15 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically active ATP analogs |
WO1997019170A1 (en) | 1995-11-21 | 1997-05-29 | Euroscreen S.A. | Receptor and nucleic acid molecule encoding said receptor |
US5652366A (en) | 1990-09-25 | 1997-07-29 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof |
US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
WO1998028300A1 (en) | 1996-12-20 | 1998-07-02 | Astra Pharmaceuticals Ltd. | Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments |
US5817660A (en) | 1991-12-06 | 1998-10-06 | Hoechst Marion Roussel, Inc. | Trans cyclopentanyl purine analogs useful as immunosuppressants |
US5831099A (en) | 1995-03-10 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Army | Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same |
WO1999005143A1 (en) | 1997-07-22 | 1999-02-04 | Astra Pharmaceuticals Ltd. | Novel compounds |
WO1999005142A1 (en) | 1997-07-22 | 1999-02-04 | Astra Pharmaceuticals Ltd. | Novel compounds |
ZA986050B (en) | 1997-07-22 | 1999-04-06 | Astra Pharma Prod | New triazolo (4,5-d)pyrimidine compounds and their use in medicaments |
WO1999031100A1 (en) | 1997-12-17 | 1999-06-24 | Astrazeneca Ab | Novel bispidine antiarrhythmic compounds |
US5948437A (en) | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
US5997089A (en) | 1997-03-18 | 1999-12-07 | Delta Tooling Co., Ltd. | Reclining seat |
EP1063231A1 (en) | 1999-06-21 | 2000-12-27 | Yamamoto Chemicals, Inc. | Polymethine compounds, method of producing the same, and use thereof |
EP0864572B1 (en) | 1995-09-01 | 2001-04-25 | Hokuriku Seiyaku Co., Ltd. | Crystal of hydrate and process for preparation thereof |
WO2001028992A2 (en) | 1999-10-18 | 2001-04-26 | Astrazeneca Ab | New oxabispidine compounds useful in the treatment of cardiac arrhythmias |
US6251910B1 (en) | 1997-07-22 | 2001-06-26 | Astrazeneca Uk Limited | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
WO2001092262A1 (en) | 2000-06-02 | 2001-12-06 | Astrazeneca Ab | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
WO2003030800A1 (en) | 2001-10-10 | 2003-04-17 | Invacare Corporation | Wheelchair suspension |
US6605600B1 (en) | 1999-11-12 | 2003-08-12 | Biogen, Incorporated | Adenosine receptor antagonists and methods of making and using the same |
US20030165563A1 (en) | 2001-12-21 | 2003-09-04 | Pfizer Inc. | Directly compressible formulations of azithromycin |
US6974868B2 (en) | 1998-12-04 | 2005-12-13 | Astrazeneca Ab | Compounds |
WO2010030224A1 (en) | 2008-09-09 | 2010-03-18 | Astrazeneca Ab | A process for preparing [1s- [1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ] -3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino] - 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates |
WO2011101740A1 (en) | 2010-02-16 | 2011-08-25 | Actavis Group Ptc Ehf | Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine |
WO2012001531A2 (en) | 2010-06-30 | 2012-01-05 | Actavis Group Ptc Ehf | Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor |
WO2012085665A2 (en) | 2010-12-20 | 2012-06-28 | Actavis Group Patc Ehf | Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof |
WO2012172426A1 (en) | 2011-06-15 | 2012-12-20 | Actavis Group Ptc Ehf | Improved process for preparing cyclopentylamine derivatives and intermediates thereof |
US8425934B2 (en) | 2006-08-21 | 2013-04-23 | Astrazeneca Ab | Pharmaceutical compositions |
WO2013079589A1 (en) | 2011-11-30 | 2013-06-06 | Actavis Group Ptc Ehf | Novel crystalline form of ticagrelor and process for the preparation thereof |
WO2013150495A2 (en) | 2012-04-05 | 2013-10-10 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
WO2014083139A1 (en) | 2012-11-29 | 2014-06-05 | Actavis Group Ptc Ehf | Novel amorphous form of ticagrelor |
WO2014102830A1 (en) | 2012-12-31 | 2014-07-03 | Megafine Pharma (P) Ltd. | A process for preparation of ticagrelor and intermediates thereof |
WO2014118808A2 (en) | 2013-02-04 | 2014-08-07 | Hetero Research Foundation | Ticagrelor solid dispersion |
WO2014195861A2 (en) | 2013-06-04 | 2014-12-11 | Dr. Reddy’S Laboratories Limited | Preparation of ticagrelor |
US9056838B2 (en) | 2011-04-06 | 2015-06-16 | Teva Pharmaceutical Industries Ltd. | Intermediates and processes for preparing Ticagrelor |
WO2016001851A1 (en) | 2014-07-02 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
US9359366B2 (en) | 2013-04-10 | 2016-06-07 | Jiangsu Hengrui Medicine Co., Ltd. | Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor |
WO2016120729A1 (en) | 2015-01-27 | 2016-08-04 | Astrazeneca Ab | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
-
1999
- 1999-11-19 TW TW088120241A patent/TWI229674B/zh active
- 1999-12-02 DK DK03025536T patent/DK1386921T3/da active
- 1999-12-02 AU AU20165/00A patent/AU766618B2/en active Active
- 1999-12-02 KR KR1020067027016A patent/KR100822602B1/ko active IP Right Grant
- 1999-12-02 EP EP03025536A patent/EP1386921B1/en not_active Expired - Lifetime
- 1999-12-02 US US09/508,195 patent/US6525060B1/en not_active Ceased
- 1999-12-02 SI SI9931026T patent/SI1386921T1/sl unknown
- 1999-12-02 ES ES03025536T patent/ES2318081T3/es not_active Expired - Lifetime
- 1999-12-02 PT PT03025536T patent/PT1386921E/pt unknown
- 1999-12-02 CA CA2351709A patent/CA2351709C/en not_active Expired - Lifetime
- 1999-12-02 CZ CZ20011962A patent/CZ295234B6/cs unknown
- 1999-12-02 ES ES99963796T patent/ES2216623T3/es not_active Expired - Lifetime
- 1999-12-02 SI SI9931059T patent/SI1386917T1/sl unknown
- 1999-12-02 US US14/976,977 patent/USRE46276E1/en active Active
- 1999-12-02 KR KR1020017006907A patent/KR100742924B1/ko active IP Right Review Request
- 1999-12-02 NZ NZ511778A patent/NZ511778A/en not_active IP Right Cessation
- 1999-12-02 PL PL348724A patent/PL201283B1/pl unknown
- 1999-12-02 CZ CZ20080600A patent/CZ300373B6/cs not_active IP Right Cessation
- 1999-12-02 CN CN99815926A patent/CN1128801C/zh not_active Ceased
- 1999-12-02 DK DK99963796T patent/DK1135391T3/da active
- 1999-12-02 IL IL14323299A patent/IL143232A0/xx unknown
- 1999-12-02 WO PCT/SE1999/002256 patent/WO2000034283A1/en active Search and Examination
- 1999-12-02 RU RU2001118284/04A patent/RU2317990C2/ru active Protection Beyond IP Right Term
- 1999-12-02 DE DE69940171T patent/DE69940171D1/de not_active Expired - Lifetime
- 1999-12-02 KR KR1020077014185A patent/KR100764417B1/ko active IP Right Grant
- 1999-12-02 EP EP10183113A patent/EP2322513A3/en not_active Withdrawn
- 1999-12-02 DE DE201112100004 patent/DE122011100004I1/de active Pending
- 1999-12-02 AT AT99963796T patent/ATE261970T1/de active
- 1999-12-02 EP EP03025535A patent/EP1386917B1/en not_active Expired - Lifetime
- 1999-12-02 AT AT03025536T patent/ATE418547T1/de active
- 1999-12-02 SI SI9930550T patent/SI1135391T1/xx unknown
- 1999-12-02 JP JP2000586728A patent/JP4202607B2/ja not_active Expired - Lifetime
- 1999-12-02 ES ES03025535T patent/ES2366902T3/es not_active Expired - Lifetime
- 1999-12-02 AT AT03025535T patent/ATE513816T1/de active
- 1999-12-02 EG EG154399A patent/EG24814A/xx active
- 1999-12-02 ID IDW00200101173A patent/ID29927A/id unknown
- 1999-12-02 PT PT99963796T patent/PT1135391E/pt unknown
- 1999-12-02 MY MYPI99005232A patent/MY121867A/en unknown
- 1999-12-02 DE DE69915675T patent/DE69915675T4/de not_active Expired - Lifetime
- 1999-12-02 CZ CZ20041089A patent/CZ300280B6/cs not_active IP Right Cessation
- 1999-12-02 EP EP99963796A patent/EP1135391B1/en not_active Expired - Lifetime
- 1999-12-02 SK SK749-2001A patent/SK286007B6/sk not_active IP Right Cessation
- 1999-12-02 EP EP03025537A patent/EP1386909A1/en not_active Withdrawn
- 1999-12-02 DK DK03025535.0T patent/DK1386917T3/da active
- 1999-12-02 KR KR1020067015291A patent/KR100776484B1/ko active IP Right Grant
- 1999-12-02 TR TR2001/01567T patent/TR200101567T2/xx unknown
- 1999-12-02 DE DE69915675A patent/DE69915675D1/de not_active Expired - Lifetime
- 1999-12-02 HU HU0105081A patent/HU228589B1/hu active Protection Beyond IP Right Term
- 1999-12-02 BR BRPI9915883A patent/BRPI9915883B8/pt not_active IP Right Cessation
- 1999-12-03 AR ARP990106165A patent/AR023920A1/es not_active Application Discontinuation
- 1999-12-27 SA SA99200848A patent/SA99200848B1/ar unknown
-
2001
- 2001-05-17 IL IL143232A patent/IL143232A/en active Protection Beyond IP Right Term
- 2001-05-18 ZA ZA200104094A patent/ZA200104094B/en unknown
- 2001-06-01 NO NO20012725A patent/NO319806B1/no active Protection Beyond IP Right Term
-
2002
- 2002-02-19 HK HK02101198.6A patent/HK1039933B/zh unknown
- 2002-02-19 HK HK04104367.3A patent/HK1061246A1/xx unknown
- 2002-12-20 US US10/323,655 patent/US6974868B2/en not_active Expired - Lifetime
-
2004
- 2004-06-28 HK HK04104617.1A patent/HK1061684A1/xx unknown
-
2005
- 2005-06-06 IL IL169013A patent/IL169013A/en not_active IP Right Cessation
- 2005-09-21 US US11/230,493 patent/US7250419B2/en not_active Expired - Lifetime
-
2006
- 2006-10-18 JP JP2006283455A patent/JP2007084551A/ja not_active Ceased
-
2007
- 2007-01-10 AR ARP070100095A patent/AR058967A2/es active IP Right Grant
- 2007-02-28 US US11/711,838 patent/US20070265282A1/en not_active Abandoned
- 2007-06-14 IL IL183969A patent/IL183969A/en not_active IP Right Cessation
- 2007-09-11 RU RU2007133926/04A patent/RU2007133926A/ru not_active Application Discontinuation
-
2008
- 2008-05-08 US US12/149,771 patent/US20080214812A1/en not_active Abandoned
- 2008-05-23 JP JP2008135275A patent/JP5043749B2/ja not_active Expired - Lifetime
-
2009
- 2009-02-26 CY CY20091100225T patent/CY1110501T1/el unknown
- 2009-04-06 IL IL198040A patent/IL198040A/en not_active IP Right Cessation
- 2009-08-11 AR ARP090103085A patent/AR072756A2/es active IP Right Grant
- 2009-11-18 US US12/591,395 patent/US20100069408A1/en not_active Abandoned
-
2010
- 2010-09-08 JP JP2010200486A patent/JP5415383B2/ja not_active Expired - Lifetime
- 2010-12-30 IL IL210398A patent/IL210398A0/en unknown
-
2011
- 2011-05-18 CY CY2011005C patent/CY2011005I2/el unknown
- 2011-05-23 FR FR11C0016C patent/FR11C0016I2/fr active Active
- 2011-05-23 NO NO2011007C patent/NO2011007I2/no unknown
- 2011-05-25 LT LTPA2011004C patent/LTC1135391I2/lt unknown
- 2011-05-31 LU LU91819C patent/LU91819I2/fr unknown
- 2011-07-21 US US13/137,125 patent/US20120165348A1/en not_active Abandoned
- 2011-08-17 CY CY20111100786T patent/CY1111759T1/el unknown
-
2012
- 2012-03-19 US US13/423,848 patent/US20130072503A1/en not_active Abandoned
- 2012-05-25 RU RU2012121883/04A patent/RU2593201C2/ru active
- 2012-10-31 US US13/665,241 patent/US20130109702A1/en not_active Abandoned
-
2013
- 2013-09-05 HU HUS1300048C patent/HUS1300048I1/hu unknown
- 2013-10-31 US US14/068,942 patent/US20140296258A1/en not_active Abandoned
-
2014
- 2014-06-20 US US14/310,315 patent/US20150152111A1/en not_active Abandoned
Patent Citations (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3106578A (en) | 1960-09-16 | 1963-10-08 | Smith Kline French Lab | Nu-phenethyl-2-phenylcyclopropylamine derivatives |
US3509129A (en) | 1967-06-08 | 1970-04-28 | Boehringer & Soehne Gmbh | Adenosine derivatives |
US3590029A (en) | 1967-08-25 | 1971-06-29 | Boehringer Mannheim Gmbh | 2-amino-adenosine derivatives |
CA994773A (en) | 1971-05-17 | 1976-08-10 | Hanspeter Fischer | 5-nitro-2,4-bis-amino-2-alkylthiopyrimidines |
US4016204A (en) | 1975-10-31 | 1977-04-05 | Nelson Research & Development Company | Method of synthesis of trans-2-phenylcyclopropylamine |
GB1561725A (en) | 1975-10-31 | 1980-02-27 | Nelson Res & Dev | Method of synthesis of trans-2-phenylcycloproylamine |
US4543255A (en) | 1984-05-10 | 1985-09-24 | Southern Research Institute | Carbocyclic analogs of purine 2'-deoxyribofuranosides |
US4742064A (en) | 1985-09-10 | 1988-05-03 | Regents Of The University Of Minnesota | Antiviral carbocyclic analogs of xylofuranosylpurines |
RU2114846C1 (ru) | 1988-01-20 | 1998-07-10 | Риджентс Оф Дзе Юниверсити Оф Миннесота | Дидезоксидидегидрокарбоциклические нуклеозиды, фармацевтическая композиция |
GB2217320A (en) | 1988-01-20 | 1989-10-25 | Univ Minnesota | Dideoxydidehydrocarbocyclic nucleosides |
WO1990006671A2 (en) | 1988-12-12 | 1990-06-28 | Palese Peter M | Methods and compositions for the prophylaxis and treatment of hepatitis b virus infections |
WO1991007405A1 (en) | 1989-11-13 | 1991-05-30 | The Board Of Regents Of Oklahoma State University | Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof |
US5652366A (en) | 1990-09-25 | 1997-07-29 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof |
WO1992012718A1 (en) | 1991-01-23 | 1992-08-06 | Gensia, Inc. | Adenosine kinase inhibitors |
WO1992017488A1 (en) | 1991-04-06 | 1992-10-15 | Fisons Plc | Atp analogues |
EP0521463A2 (de) | 1991-07-04 | 1993-01-07 | Hoechst Aktiengesellschaft | Cyclisch substituierte Cycloalkyltriole, Verfahren und Zwischenprodukte zu ihrer Herstellung sowie ihre Verwendung als antivirale und antiparasitäre Mittel |
US5631259A (en) | 1991-07-04 | 1997-05-20 | Hoechst Aktiengesellschaft | Cycloalkltriols containing cyclic substituents, processes and intermediate products for their preparation and their use as antiviral and antiparasitic agents |
US5288726A (en) | 1991-09-09 | 1994-02-22 | Ube Industries Limited | Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof and their preparation and uses for inhibiting blood platelet aggregation |
US5817660A (en) | 1991-12-06 | 1998-10-06 | Hoechst Marion Roussel, Inc. | Trans cyclopentanyl purine analogs useful as immunosuppressants |
US5338725A (en) | 1992-06-30 | 1994-08-16 | The Research Foundation Of The State University Of New York | Anti-aggregatory agents for platelets |
WO1994017803A1 (en) | 1993-02-03 | 1994-08-18 | Gensia, Inc. | Adenosine kinase inhibitors |
WO1994018216A1 (en) | 1993-02-10 | 1994-08-18 | Astra Pharmaceuticals Limited | N-alkyl-2-substituted atp analogues |
US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
US5620676A (en) | 1994-03-08 | 1997-04-15 | The United States Of America As Represented By The Department Of Health And Human Services | Biologically active ATP analogs |
US5831099A (en) | 1995-03-10 | 1998-11-03 | The United States Of America As Represented By The Secretary Of The Army | Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same |
WO1996029345A1 (en) | 1995-03-23 | 1996-09-26 | The Trustees Of The University Of Pennsylvania | Novel inotropic agents |
WO1996040686A1 (en) | 1995-06-07 | 1996-12-19 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
US5747496A (en) | 1995-07-11 | 1998-05-05 | Astra Pharmaceuticals Limited | Inhibitors of platelet aggregation |
WO1997003084A1 (en) | 1995-07-11 | 1997-01-30 | Astra Pharmaceuticals Ltd. | New inhibitors of platelet aggregation |
EP0864572B1 (en) | 1995-09-01 | 2001-04-25 | Hokuriku Seiyaku Co., Ltd. | Crystal of hydrate and process for preparation thereof |
WO1997019170A1 (en) | 1995-11-21 | 1997-05-29 | Euroscreen S.A. | Receptor and nucleic acid molecule encoding said receptor |
US5948437A (en) | 1996-05-23 | 1999-09-07 | Zeneca Limited | Pharmaceutical compositions using thiazepine |
WO1998028300A1 (en) | 1996-12-20 | 1998-07-02 | Astra Pharmaceuticals Ltd. | Triazolo[4,5-d]pyrimidinyl derivatives and their use as medicaments |
US5997089A (en) | 1997-03-18 | 1999-12-07 | Delta Tooling Co., Ltd. | Reclining seat |
US6156756A (en) | 1997-07-22 | 2000-12-05 | Astrazeneca Uk Limited | Triazolo [4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation |
US6251910B1 (en) | 1997-07-22 | 2001-06-26 | Astrazeneca Uk Limited | 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists |
ZA986050B (en) | 1997-07-22 | 1999-04-06 | Astra Pharma Prod | New triazolo (4,5-d)pyrimidine compounds and their use in medicaments |
WO1999005142A1 (en) | 1997-07-22 | 1999-02-04 | Astra Pharmaceuticals Ltd. | Novel compounds |
WO1999005143A1 (en) | 1997-07-22 | 1999-02-04 | Astra Pharmaceuticals Ltd. | Novel compounds |
KR100535837B1 (ko) | 1997-07-22 | 2006-01-12 | 아스트라 파마슈티칼스 리미티드 | 신규 화합물 |
WO1999031100A1 (en) | 1997-12-17 | 1999-06-24 | Astrazeneca Ab | Novel bispidine antiarrhythmic compounds |
US6974868B2 (en) | 1998-12-04 | 2005-12-13 | Astrazeneca Ab | Compounds |
US20080214812A1 (en) | 1998-12-04 | 2008-09-04 | Astrazeneca Ab | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US20120165348A1 (en) | 1998-12-04 | 2012-06-28 | Astrazeneca Ab | Novel compounds |
US20130109702A1 (en) | 1998-12-04 | 2013-05-02 | Astrazeneca Ab | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US20100069408A1 (en) | 1998-12-04 | 2010-03-18 | Astrazeneca Ab | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US20140296258A1 (en) | 1998-12-04 | 2014-10-02 | Astrazeneca Uk Limited | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibiton |
US20130072503A1 (en) | 1998-12-04 | 2013-03-21 | Astrazeneca | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US7250419B2 (en) | 1998-12-04 | 2007-07-31 | Astrazeneca Ab | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US20150152111A1 (en) | 1998-12-04 | 2015-06-04 | Astrazeneca Uk Limited | Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition |
US20070265282A1 (en) | 1998-12-04 | 2007-11-15 | Astrazeneca Ab | Novel compounds |
EP1063231A1 (en) | 1999-06-21 | 2000-12-27 | Yamamoto Chemicals, Inc. | Polymethine compounds, method of producing the same, and use thereof |
WO2001028992A2 (en) | 1999-10-18 | 2001-04-26 | Astrazeneca Ab | New oxabispidine compounds useful in the treatment of cardiac arrhythmias |
US6559143B1 (en) | 1999-10-18 | 2003-05-06 | Astrazeneca Ab | Oxabispidine compounds useful in the treatment of cardiac arrhyythmias |
US6605600B1 (en) | 1999-11-12 | 2003-08-12 | Biogen, Incorporated | Adenosine receptor antagonists and methods of making and using the same |
WO2001092262A1 (en) | 2000-06-02 | 2001-12-06 | Astrazeneca Ab | New crystalline and amorphous form of a triazolo(4,5-d)pyrimidine compound |
US7265124B2 (en) | 2000-06-02 | 2007-09-04 | Astrazeneca Ab | Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound |
WO2003030800A1 (en) | 2001-10-10 | 2003-04-17 | Invacare Corporation | Wheelchair suspension |
US20030165563A1 (en) | 2001-12-21 | 2003-09-04 | Pfizer Inc. | Directly compressible formulations of azithromycin |
US8425934B2 (en) | 2006-08-21 | 2013-04-23 | Astrazeneca Ab | Pharmaceutical compositions |
WO2010030224A1 (en) | 2008-09-09 | 2010-03-18 | Astrazeneca Ab | A process for preparing [1s- [1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ] -3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino] - 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates |
WO2011101740A1 (en) | 2010-02-16 | 2011-08-25 | Actavis Group Ptc Ehf | Improved processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine |
WO2012001531A2 (en) | 2010-06-30 | 2012-01-05 | Actavis Group Ptc Ehf | Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor |
WO2012085665A2 (en) | 2010-12-20 | 2012-06-28 | Actavis Group Patc Ehf | Novel processes for preparing triazolo[4,5-d]pyrimidine derivatives and intermediates thereof |
US9056838B2 (en) | 2011-04-06 | 2015-06-16 | Teva Pharmaceutical Industries Ltd. | Intermediates and processes for preparing Ticagrelor |
WO2012172426A1 (en) | 2011-06-15 | 2012-12-20 | Actavis Group Ptc Ehf | Improved process for preparing cyclopentylamine derivatives and intermediates thereof |
WO2013079589A1 (en) | 2011-11-30 | 2013-06-06 | Actavis Group Ptc Ehf | Novel crystalline form of ticagrelor and process for the preparation thereof |
WO2013150495A2 (en) | 2012-04-05 | 2013-10-10 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
US20150073146A1 (en) | 2012-04-05 | 2015-03-12 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
WO2014083139A1 (en) | 2012-11-29 | 2014-06-05 | Actavis Group Ptc Ehf | Novel amorphous form of ticagrelor |
WO2014102830A1 (en) | 2012-12-31 | 2014-07-03 | Megafine Pharma (P) Ltd. | A process for preparation of ticagrelor and intermediates thereof |
WO2014118808A2 (en) | 2013-02-04 | 2014-08-07 | Hetero Research Foundation | Ticagrelor solid dispersion |
US9359366B2 (en) | 2013-04-10 | 2016-06-07 | Jiangsu Hengrui Medicine Co., Ltd. | Intermediate of Ticagrelor and preparation method therefor, and preparation method for Ticagrelor |
WO2014195861A2 (en) | 2013-06-04 | 2014-12-11 | Dr. Reddy’S Laboratories Limited | Preparation of ticagrelor |
WO2016001851A1 (en) | 2014-07-02 | 2016-01-07 | Dr. Reddy's Laboratories Limited | Preparation of ticagrelor |
WO2016120729A1 (en) | 2015-01-27 | 2016-08-04 | Astrazeneca Ab | Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction |
Non-Patent Citations (182)
Title |
---|
1987 FDA Guideline for Submitting and Supporting Documentation in Drug Applications for the Manufacture of Drug Substances. |
3721-26-4 Registry, Cyclopropanamine, 2-phenyl-, (1R-trans)-Cyclopropylamine, 2-phenyl-, trans-(-)- Entered STN: Nov. 16, 1984, (see also 13531-35-6 Registry and 69684-89-5 Registry for other stereo isomers) 69684-89-5 Registry, Cyclopropanamine, 2-(3-chlorophenyl)-, hydrochloride, trans-, Entered STN: Feb. 8, 1991. |
A Guide to IUPAC Nomenclature of Organic Compounds Recommendations 1993, 149-155 (R. Panico et al. eds., 1993). |
Agatonovic-Kustrin et al., Powder Diffractomertic Assay of Two Polymorphic Forms of Ranitidine Hydrochloride, Int. J. of Pharmaceutics, 184:107-114 (1999). |
Albert, Chemistry of 8-Azapurines (1,2,3-Triazolo[4,5-d]pyrimidines), Advances in Heterocyclic Chemistry, 39:117-180 (1986). |
Alberts et al., Molecular Biology of the Cell, 4th ed., p. G:2 (2002). |
Angiolillo, The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day, Drugs. 72(16):2087-116 (2012). |
AstraZeneca's Proposed Construction of Claim Terms and Intrinsic and Extrinsic Support, Cons. Civil Action No. 15-1000-RGA (Sep. 1, 2016). |
Aukland et al., Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication, J. Clin. Pathol. 35:740-743 (1982). |
Awni et al., The Effect of Mild or Moderate Hepatic Impairment (Cirrhosis) on the Pharmacokinetics of Zileuton, Clin. Pharacokinet 29 (Suppl. 2): 49-61 (1995). |
Balzarini et al., Human Immunodeficiency Virus Type 1 Drug-Resistance Patterns with Different 1[(2-Hydroxyethoxy) methyl]-6-(phenylthio)thymine Derivatives, Mol. Pharmacology 44:694-701 (1993). |
Bassand, Unmet needs in antiplatelet therapy, Eur. Heart. J. 10(supp D):D3-11 (2008). |
Beck et al., A New Family of Mesoporous Molecular Sieves Prepared with Liquid Crystal Templates, J. Am. Chem. Soc., 114:10834-10843 (1992). |
Becker et al., Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: a foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies, Thromb. Haemost. 103 (3):535-44 (2010). |
Becker, Emerging constructs to maintain safety among patients with acute coronary syndromes requiring surgical coronary revascularization, Eur. Heart J. 10(supp D):D12-22 (2008). |
Begstrom et al., Fluorine Substituted Analogs of Nucleic Acid Components, in Fluorine-Containing Molecules: Structure, Reactivity, Synthesis, and Applications 259-308 (J. F. Liebman et al. eds., 1988). |
Berger et al., Is there an association between aspirin dosing and cardiac and bleeding events after treatment of acute coronary syndrome? A Systematic Review of the Literature., Am. Heart J. 164(2):153-62 (2012). |
Berger, Aspirin, Clopidogrel, and Ticagrelor in Acute Coronary Syndromes, Am. J. Cardiol. 112(5):737-45 (2013). |
Bernstein, Polymorphism in Molecular Crystals, pp. 111, 117 (2002). |
Berstein, Conformational Polymorphism, in Organic Solid State Chemistry 471-518 (G. R. Desiraju ed., 1987). |
Berstein, Polymorphism in Molecular Crystals (2002), p. 252. |
Bhagwat et al., P2 Purine and Pyrimidine Receptors: Emerging Superfamilies of G-Protein-Coupled and Ligand-Gated Ion Channel Receptors, Eur. J. Med. Chem., 32:183-193 (1997). |
Blackwood et al., Chemical Abstracts Service Chemical Registry System. 13. Enhanced Handling of Stereochemistry, J. of Chem. Info. and Comput. Sci., 31(2):204-212 (1991). |
Blackwood et al., Chemical Abstracts Stereochemical Nomenclature of Organic Substances in Ninth Collective Period (1972-1976), J. of Chem. Info. and Comput. Sci., 15(2):67-72 (1975). |
Bode et al., The use of antiplatelet agents following percutaneous coronary intervention: focus on late stent thrombosis, Eur. Heart J. 9 (supp D):D10-19 (2007). |
Borka, Crystal Polymorphism of Pharmaceuticals, Acta. Pharm. Jugosl. 40:71-94 (1990). |
Brittain et al., Effects of Pharmaceutical Processing on Drug Polymorphs and Solvates, in Polymorphism in Pharmaceutical Solids 331-361 (H. G. Brittain ed., 1999). |
Brittain, Polymorphism in Pharmaceutical Solids, pp. 227-278 (1999). |
Brittain, Preface to Polymorphism in Pharmaceutical Solids, Drugs and Pharmaceutical Studies, 95:iii-v (H. G. Brittain, ed., 1999). |
Brook, The Nomenclature of Relative Stereochemistry, J. of Chem. Ed., 64(3):218-220 (1987). |
Bruger's Medicinal Chemistry, Fourth Edition, pp. 58-59 (1980). |
Bryn et al., Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations, Pharmacutical Research vol. 12, No. 7 (1995). |
Bryn et al., Solid-State Chemistry of Drugs, 2d ed., pp. 490-492 (1999). |
Bryn et al., Solid-State Chemistry of Drugs, 2d ed., pp. 59, 63, 64 (1999). |
Byrn et al., Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations, Pharmaceutical Research, 12 (7):945-954 (1995). |
Byrn et al., Solid State Chemistry of Drugs, 2d ed., pp. 266-278 (1999). |
Caira, Crystalline Polymorphism of Organic Compounds, Top. Curr. Chem. 198:163-208 (1998). |
Carroll et al., Statistical evaluation and analysis of regional interactions: The Plato trial case study, Stat. Biopharm. Res. 5(2):102-4 (2013). |
Cattaneo et al., Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance, J. Am. Coll. Cardiol. 63(23):2503-9 (2014). |
Cayla et al., Updates and Current Recommendations for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: What It Means for Clinical Practice, Am. J. Cardiol. 115(5 Supp):10A-22A (2015). |
Chambers Science and Technology Dictionary, p. 24 (1988). |
Chapman et al, Difluoramination of Heterocyclic Ketones: Control of Microbasicity, Journal of Organic Chemistry 63(5), pp. 1566-1570 (1998). |
Chapman et al, Nitrolysis of a Highly Deactivated Amide by Protonitronium, Synthesis and Structure of HNFX, Journal of Organic Chemistry 64(3), pp. 960-965 (1999). |
Chemical Abstracts Index Guide, Appendix IV, ¶¶202-203 (1997). |
Chemical Abstracts Index Guide, Appendix IV, ��202-203 (1997). |
Chlud, Zur Anwendung von NSAR-Topika bei irritierten and dekompensierten Arthrosen, Wiener Medizinische Wochenschrift 149(19/20):546-547 (1999). |
Clark et al., Managing the acute coronary syndrome patient: Evidence based recommendations for anti-platelet therapy, Heart & Lung. 44(2):141-9 (2015). |
Clopidogrel (PLAVIX) FDA Label (2010). |
Connick et al., Fluorine-19 Nuclear Magnetic Resonance Studies of Binary and Ternary Complexes of Thymidylate Synthase Utilizing a Fluorine-Labeled Folate Analogue, Biochem 32:9888-9895 (1993). |
Cross et al., Rules for the Nomenclature of Organic Chemistry—Section E: Stereochemistry (Recommendations 1974), Pure & Appl. Chem., 45(1-B):13-30 (1976). |
Cusack et al., Effects of Phosphate-Modified Analogs of Adenosine 5′-Diphosphate and Adenosine 5′-Triphosphate At P2T-Purinoreceptors Mediating Human Platelet Activation by ADP, Drug Dev. Res. 37:212-222 (1996). |
Cusack et al., Effects of Phosphate-Modified Analogs of Adenosine 5'-Diphosphate and Adenosine 5'-Triphosphate At P2T-Purinoreceptors Mediating Human Platelet Activation by ADP, Drug Dev. Res. 37:212-222 (1996). |
Daly et al., Structure-Activity Relationships for N6-Substituted Adenosines at a Brain A1-Adenosine Receptor with a Comparison to an A2-Adenosine Receptor Regulating Coronary Blood Flow, Biochemical Pharmacology 35:2467-81 (1986). |
Dave et al, Facile Preparation of 3,7-Diazabicyclo[3.3.0]octane and 3,7,10-Triheterocyclic [3.3.3]Propellane Ring Systems from 1,5-Diazacyclooctane 3,7-Derivatives, Journal of Organic Chemistry 61(25), pp. 8897-8903 (1996). |
Deeks, Ticagrelor: A review of its use in the management of acute coronary syndromes, Drugs 71(7):909-33 (2011). |
Defendant Watson Laboratories, Inc.'s Answer to Complaint, Defenses, and Counterclaims in AstraZeneca, LP v. Watson Laboratories, Inc., Civil Action No. 1:16-338-RGA. |
Defendants' Initial Invalidity and Uneforceability Contentions in Civil Action No. 15-1000-RGA (dated Jun. 24, 2016). |
Defendants' Initial Proposed Claim Constructions, Cons. Civil Action No. 15-1000-RGA (Sep. 1, 2016). |
Defendants' Preliminary Identification of Evidence to Rebut Plaintiffs' Proposed Claim Constructions, Cons. Civil Action No. 15-1000-RGA (Sep. 26, 2016). |
Dobesh et al., Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety, Pharmacotherapy, 34 (10):1077-90 (2014). |
Dorwald F.A., Side Reactions in Organic Synthesis, Wiley: VCH, Weinheim p. IX of Preface (2005). |
Elements of X-ray Diffraction, Second Edition (Ed. Cullity), pp. 397-420 (1978). |
Elion et al., Selectivity of Action of an Antiherpetic Agent, 9-(2-hydroxyethoxymethyl)guanine, Proc. Natl. Acad. Sci., 74 (12):5716-5720 (1977). |
F. Carey, A Brief History of Systematic Organic Nomenclature, from Organic Chemistry, Fourth Edition, p. 63 (2000). |
FDA Center for Drug Evaluation and Research,Guideline for Submitting Supporting Documentation in Drug Applications for the Manufacture of Drug Substances (1987). |
FDA Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances (2000). |
Filler et al., Fluorine in Biomedicinal Chemistry: An Overview of Recent Advances and Selected Topics, Biomedicinal Aspects of Fluorine Chemistry 1-32 (R. Filler and Y. Kobayashi eds., 1982). |
Filler, Biologically-Active Fluorochemicals, J. Fluorine Chemistry 33:361-375 (1986). |
Filler, Fluorinated Compounds of Medicinal Interest, ChemTech Dec. (1974). |
Foody, Antiplatelet Therapy in Women with Acute Coronary Syndrome, J. of Family Practice, 63(2 Supp):S3-8 (2014). |
Fox et al., Nomenclature of Organic Compounds, 2d ed., Chapter 30, "Stereoisomers" (2001). |
Grant & Hackh's Chemical Dictionary, 5th ed., p. 24 (1987). |
Guile, Chemical Abstracts, vol. 130, 168386 (1999). |
Guilllory, Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids, chapter in Polymorphism in Pharmaceutical Solids, 183-226 (1999). |
Haleblain et al., Pharmaceutical Applications of Polymorphism, J. of Pharmaceutical Sciences, vol. 58, No. 8, 911-929 (1969). |
Haleblian et al., Pharmaceutical Applications of Polymorphism, J. of Pharmacutical Sci., vol. 58, No. 8 (1969). |
Haleblian et al., Pharmaceutical Applications of Polymorphism, J. Pharm. Sci. 58(8):911-929 (1969). |
Hanawalt, Chemical Analysis of X-Ray Diffraction, Powder Diffraction vol. 1 No. 2 pp. 2-14 (1986). |
Heidelberger et al., Fluorinated Pyrimidines and Their Nucleosides, Adv. Enzymol. And Related Areas of Mol. Bio., 54:57-119 (1983). |
Humphries et al., "Daring to be Different": The Discovery of Ticagrelor, The Handbook of Medicinal Chemistry, Principals and Practice (2015). |
Humphries et al., A Novel Series of P2T Purinoceptor Antagonists: Definition of the Role of ADP in Arterial Thrombosis, TiPS 16:179-181 (1995). |
Humphries et al., FPL 66096: A Novel, Highly Potent and Selective Antagonist at Human Platelet P2T-Purinoceptors, Br. J. Pharmacol. 113:1057-1063 (1994). |
Humphries et al., Pharmacological Profile of the Novel P2T-Purinoceptor Antagonist, FPL 67085 in vitro and in the Anesthetized Rat in vivo, Br. J. Pharmacol. 115:1110-1116 (1995). |
Huo et al., Challenges and solutions in medically managed ACS in the Asia-Pacific region: Expert recommendations from the Asia-Pacific ACS Medical Management Working Group, Int. J. Cardiol. 183:63-75 (2015). |
Husted et al., Ticagrelor: The first reversibly binding oral P2Y12 receptor antagonist, Cardiovasc. Ther. 27(4):259-74 (2009). |
Husted, Evaluating the risk—benefit profile of the direct-acting P2Y12 inhibitor ticagrelor in acute coronary syndromes, Postgrad. Med. 123(6):79-90 (2011). |
Husted, New developments in oral antiplatelet therapy, Eur. Heart J. 9 (suppl D) D:20-7 (2007). |
Husted, Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents, Fundam. Clin. Pharmacol. 23 (1):1-9 (2009). |
ICH Harmonised Tripatite Guideline, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances Q6A (1999). |
ICH Harmonized Tripartite Guideline, Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Q6A (1999). |
Introduction to X-ray Powder Diffractometry (Eds. Jenkins and Snyder), pp. 261-286 (1996). |
Introduction to X-ray Powder Diffractometry (Eds. Jenkins and Snyder), pp. 319-353 (1996). |
J. Brian Houston; Commentary, "Utility of In Vitro Drug Metabolism Data in Predicting In Vivo Metabolic Clearance; Biochemical Pharmacology", vol. 47, No. 9, pp. 1469-1479, 1994. |
Jacobson et al., Search for New Purine-and Ribose-Modified Adenosine Analogues as Selective Agonists and Antagonists at Adenosine Receptors, J. Med. Chem. 38:1174-1188 (1995). |
Jacobson et al., Structure-Activity Relationships of 9-Alkyladenine and Ribose-Modified Adenosine Derivatives at Rat A3 Adenosine Receptors, J Med. Chem. 38:1720-1735 (1995). |
Jin et al., Molecular Basis for ADP-induced Platelet Activation, The Journal of Biological Chemistry, vol. 273, No. 4, pp. 2030-2034(1998). |
Jones et al., Chemistry—Molecules, Matter, and Change, 4th ed., p. B2 (2000). |
Jun. 16, 2015 Revocation Petition by Micro Labs Ltd. against Indian Patent No. 247984. |
Jun. 4, 2016 Counter Statement by Respondent AstraZeneca AB in response to Revocation Petition by Micro Labs Ltd. against Indian Patent No. 209907. |
Jung et al., Total Synthesis of Neplanocin A., Helvetica Chimica Acta, vol. 66, No. 7, pp. 1915-1921 (1983). |
Koomen, Synthesis and Biological Properties of Selected Nucleoside Analogues, Recl. Tray. Chim. Pays-Bas 112:51-65 (1993). |
Lewis et al., Topics in Molecular Pharmacology (Burgen, A. S. V., & Roberts, G. C. K., Eds.) 1:169-219 (1981). |
Maehr, A Proposed New Convention for Graphic Presentation of Molecular Geometry and Topography, J. of Chem. Ed., 62(2):114-120 (1985). |
Mar. 27, 2015 Korean Appeal For Judgment against Korean Patent No. 724,924; Claimant: Bio and Chemical R&D. |
Mar. 27, 2015 Korean Appeal For Judgment against Korean Patent No. 724,924; Claimant: Daewon Pharmaceutical Co. |
Mar. 27, 2015 Korean Appeal For Judgment against Korean Patent No. 724,924; Claimant: Daewoong Pharmacutical Co. |
Mar. 27, 2015 Korean Appeal For Judgment against Korean Patent No. 724,924; Claimant: JW Pharmaceutical Corp. |
Mar. 30, 2015 Korean Appeal For Judgment against Korean Patent No. 724,924; Claimant: Kukje Pharma Ind. Co., Ltd. |
Martindale Thirty-third edition; "The Complete Drug Reference"; Pharmaceutical Press; pp. 1086-1089. |
McCrone, Polymorphism, Chapter 8 in Physics and Chemistry of the Organic Solid State (1965). |
McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed., p. 68 (2003). |
Melandri et al., Benefit of Adding Low Molecular Weight Heparin to the Conventional Treatment of Stable Angina Pectoris A Double-Blind, Randomized, Placebo-Controlled Trial, Circulation 88:2517-2523 (1993). |
Mistry et al., Glucuronidation In Vitro and In Vivo Comparison of Intestinal and Hepatic Conjugation of Morphine, Naloxone, and Buprenorphine; The American Society for Pharmacology and Experimental Therapeutics, vol. 15, No. 5; pp. 710-717 (1987). |
Morrison et al., Organic Chemistry, 3d ed., pp. 79-83 (1973). |
Mosby's Medical Dictionary, revised 2d ed., p. 40 (1987). |
Moss, Basic Terminology of Stereochemistry (IUPAC Recommendations 1996), Pure & Appl. Chem., 68 (12):2193-2222 (1996). |
Naming and Indexing of Chemical Substances for Chemical Abstracts 2007 Edition (2008), pp. 1-154. |
Naming and Indexing of Chemical Substances for Chemical Abstracts 2007 Edition (Chemical Abstract Service, 2008), p. 1. |
Nasipuri, Stereochemistry of Organic Compounds, Principles and Applications, Chapter 4 (1994). |
Nassim et al., The Short-Acting P2T-Purinoceptor Antagonist, FPL 67085, Reliably, Reversibly, and Safely Inhibits ADP-Induced Platelet Aggregation ex vivo in Man, Br. J. Clin. Pharmacol. 39(1):98P (1995). |
Nov. 24, 2015 Revocation Petition by Micro Labs Ltd. against Indian Patent No. 209907. |
O'Hagan et al., Some Influences of Fluorine in Bioorganic Chemistry, Chem. Commun. 645-652 (1997). |
Owen et al., AZD6140. Antiplatelet therapy P2Y12 (P2T) receptor antagonist., Drugs Fut. 32(10):845-53 (2007). |
Paragraph IV Certification Letter #1, dated Oct. 1, 2015, pp. 1-34. |
Paragraph IV Certification Letter #2, dated Sep. 23, 2015, pp. 1-50. |
Paragraph IV Certification Letter #3, dated Sep. 18, 2015, pp. 1-72. |
Paragraph IV Certification Letter #4, dated Sep. 17, 2015, pp. 1-145. |
Paragraph IV Certification Letter #5, dated Oct. 5, 2015, pp. 1-67. |
Paragraph IV Certification Letter #6, dated Oct. 3, 2015, pp. 1-58 and Appendix pp. 1-8. |
Paragraph IV Certification Letter #7, dated May 4, 2016. |
Park et al., Effects of Fluorine Substitution on Drug Metabolism: Pharmacological and Toxicological Implications, Drug Metab. Rev. 26(3):605-643 (1994). |
Patani et al., Bioisosterism: A Rational Approach in Drug Design, Chem. Rev. 96:3147-3176 (1996). |
Paudler et al., 1,5-Bis(p-toluenesulfonyl)-3,7-Dihydroxyoctahydro-1,5-diazocine, Journal of Organic Chemistry, 31(1), pp. 277-280 (1966). |
Paudler et al., 3,7-Disubstituted octahydro-1,5-diazocines. Their conversion into tetrahydro-1,5-diazocines and to ring-contracted products, Journal of Organic Chemistry; 32(8), pp. 2425-2430 (1967). |
Pavia et al., Introduction to Organic Laboratory Techniques, 2nd Ed., 481-491 (1982). |
Pivia et al., Introduction to Oraganic Laboratory Techniques, 2d Ed. (1982). |
Price et al., A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease, J. Thromb. Thrombolysis. 39(1):8-14 (2015). |
Print out from http:/webbok.nist.gov/cgi/cbook.cgi?ID=87694 for "(R,R)-Tartaric acid". |
Proposed Construction of Claim Terms and Intrinsic and Extrinsic Support, Cons. Civil Action No. 15-1000-RGA (Sep. 26, 2016). |
Puri et al., Modulation of Platelet Responses by 2-[3-(Bromo-2-oxopropylthio)]-adenosine . . . , Archives of Biochemistry and Biophysics, vol. 343, No. 1, pp. 140-145 (1997). |
Radebaugh et al., Preformulation, from The Science and Pharmacy, Chapter 38, (1995). |
Raw et al., Regulatory Considerations of Pharmaceutical Solid Polymorphism in Abbreviated New Drug Applications (ANDAs), Adv. Drug. Deliv. Rev. 56:397-414 (2004). |
Rodrigues, Commentary, Use of In Vitro Human Metabolism Studies in Drug Development, Biochemical Pharmacology, vol. 48, No. 12, pp. 2147-2156 (1994). |
Roffman, Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes, J. of Pharmacy Practice (2015). |
Rules of Carbohydrate Nomenclature, J. of Organic Chem., 28(2):281-291 (1963). |
Santi et al., 5-Fluoro-2′-Deoxyuridylate: Covalent Complex with Thymidylate Synthetase, Proc. Nat. Acad. Sci. 69:1855-1857 (1972). |
Santi et al., 5-Fluoro-2'-Deoxyuridylate: Covalent Complex with Thymidylate Synthetase, Proc. Nat. Acad. Sci. 69:1855-1857 (1972). |
Santi, Perspectives on the Design and Biochemical Pharmacology of Inhibitors of Thymidylate Synthetase, J. Med. Chem. 23:103-111 (1980). |
Sherry-McKenna, et al., Monoamine oxidase inhibitors: effects on tryptophan concentrations in rat brain, J. Neural. Transm. (Supp) 41:155-163 (1994). |
Siddiqui et al., Search for New Purine- and Ribose-Modified Adenosine Analogues as Selective Agonists and Antagonists at Adenosine Receptors, J. Med. Chem. 38:1174-1188 (1995). |
Sorrell, Organic Chemistry, pp. 52-55 (1999). |
Springthorpe et al., From ATP to AZD6140: The discovery of an orally active reversible P2Y12 receptor antagonist for the prevention of thrombosis, Bioorg Med Chem Lett. 17(21):6013-8 (2007). |
Stetter, Synthese des 1.3-Diaza-6-oxa-adamantans, Chemische Berichte, 96(11), pp. 2827-2830 (1963). |
Storey, New developments in antiplatelet therapy, Eur. Heart J. 10(supp D):D30-7 (2008). |
Supplemental Paragraph IV Certification Letter #3, dated Jul. 27, 2016, pp. 1-42. |
Tantry et al., AZD6140, Expert Opin. Investig. Drugs 16(2):225-9 (2007). |
Tantry et al., Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease, Expert Rev. Cardiovasc. Ther. 11(4):447-62 (2013). |
The Practice of Medicinal Chemistry (Camille G. Wermuth, 1st ed.), pp. 617, 631, 636 (1996). |
Threlfall, Analysis of Organic Polymorphs, A Review, Analyst 120:2435-2460 (1995). |
Thurlow, Chemical Nomenclature, pp. 83-84 (1998). |
Tiwari et al., Risk factors for cardiovascular events and bleeding complications following non-cardiac surgery or procedure in patients with drug eluting stent placement, Heart Asia. 6:69-75 (2014). |
Tompkinson et al., P2T Purinoceptor Antagonists. A QSAR Study of Some 2-Substituted ATP Analogues, J. Pharm. Pharmacol. 48:206-209 (1996). |
Trelfall, Analysis of Organic Polymorphs A Review, Analyst V. 120 (1995). |
United States Pharmacopeia USP 23, NF 18 <941> "X-Ray Diffraction", pp. 1843-1844 (1995). |
United States Pharmacopeia USP 24, NF 19 <941> "X-Ray Diffraction", pp. 2005-2007 (2000). |
United States Pharmacopeia USP 28, NF 23 <941> "X-Ray Diffraction", pp. 2513-2515 (2005). |
Van de Werf, Dual antiplatelet therapy in high-risk patients, Eur. Heart J. 9(supp D):D3-9 (2007). |
van Giezen et al., Preclinical and clinical studies with selective reversible direct P2Y12 antagonists, Semin. Thromb. Hemost. 31(2):195-204 (2005). |
van Giezen, Optimizing platelet inhibition, Eur. Heart J. 10(supp D):D23-9 (2008). |
Vartuli et al., Effect of Surfactant/Silica Molar Ratios on the Formation of Mesoporous Molecular Sieves: Inorganic Mimicry of Surfactant Liquid-Crystal Phases and Mechanistic Implications, Chem. Mater. 6:2317-2326 (1994). |
Vengoechea, Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy, Hospital Practice. Aug. 42(3):33-47 (2014). |
Villgarda et al., trans-2-Aryl-N,N-dipropylcyclopropylamines: Synthesis and Interactions with 5-HT1A Receptors, Journal of Medical Chemistry; vol. 39, No. 7; pp. 1485-1493 (1996); SP002262871. |
Vippagunta et al., Advanced Drug Delivery Reviews, 48; pp. 3-26 (2001). |
Wallentin, Dual antiplatelet therapy in the drug-eluting stent era, Eur Heart J. 10(supp D): D38-44 (2008). |
Warner et al., Anti-platelet therapy: cyclooxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy, Br. J. Clin. Pharmacol. 72(4):619-33 (2011). |
Webster's Ninth New Collegiate Dictionary, p. 70 (1986). |
Weiser, Postmytocardinal Infraction Syndrome, Circulation 20:371-380 (1951). |
Weisgerber, Chemical Abstracts Service Chemical Registry System: History, Scope, and Impacts, J. of the American Soc. for Info. Sci. 48(4):349-360 (1997). |
Weissbuch et al., Molecular Recognition at Crystal Interface, Science 253:637-645 (1991). |
Weissbuch et al., Understanding and Control of Nucleation, Habit, Dissolution and Structure of Two- and Three-Dimensional Crystals Using 'Tailor-Made' Auxiliaries, Acta Cryst. B51:115-148 (1995). |
Wermuth, The Practice of Medicinal Chemistry, Academic Press Inc., p. 182-185, 226-228 and 346-348 (1996). |
Yu et al., Physical Characterization of Polymorphic Drugs: An Integrated Characterized Strategy, PSTT 1:118-127 (1998). |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE46276E1 (en) | Triazolo(4,5-D)pyrimidine compounds | |
MXPA01005531A (en) | Novel triazolo(4,5-d)pyrimidine compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: BRILINTA (TICAGRELOR); REQUESTED FOR 1794 DAYS Filing date: 20110909 Expiry date: 20191202 |
|
PTEG | Grant of a patent term extension |
Free format text: PRODUCT NAME: BRILINTA (TICAGRELOR) Filing date: 20110909 Expiry date: 20191202 |